BioSpace News Archive

Ginkgo Bioworks announced its participation in the 27th American Society of Gene & Cell Therapy Annual Meeting, May 7-11, in Baltimore, MD. Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics.

Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer

Bristol Myers Squibb announced that the U.S. FDA has accepted the Biologics License Application for the subcutaneous formulation of Opdivo® co-formulated with Halozyme’s proprietary recombinant human hyaluronidase across all previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy combination therapy, or in combination with chemotherapy or cabozantinib.

Stoke Therapeutics, Inc. reported financial results for the first quarter of 2024 and provided business updates including those related to STK-001, the Company’s proprietary antisense oligonucleotide which is in development by Stoke as the first potential medicine to address the genetic cause of Dravet syndrome.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, announced it received a Notice of Allowance from the European Patent Office for its patent application titled “An A3 Adenosine Receptor Ligands For Use in Treatment of a Sexual Dysfunction”.

bluebird bio, Inc. announced that it has completed the first commercial cell collection for LYFGENIA, a one-time gene therapy for the treatment of sickle cell disease in patients with a history of vaso-occlusive events.

SAB Biotherapeutics announced that Jay Skyler, MD, MACP, FRCP has been appointed to the company’s Board of Directors.

Soligenix, Inc. announced that the Company will deliver a corporate presentation at the upcoming conferences below.

Gossamer Bio, Inc. and Chiesi Farmaceutici S.p.A announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib.

Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, announced that its first quarter 2024 financial results will be released on Monday, May 13, 2024 before the U.S. financial markets open.